(RTTNews) - Charles River Laboratories International Inc. (CRL) will host a conference call at 9:00 AM ET on November 4th, 2026, to discuss Q3 26 earnings results.

Charles River Laboratories International Q3 26 Earnings Conference Call At 9:00 AM ET 

(RTTNews) - Charles River Laboratories International, Inc. (CRL), a provider of drug discovery and development services, Wednesday raised its 2026 outlook for organic revenue growth and earnings per share.

Charles River Laboratories Lifts Annual Outlook- Update 

(RTTNews) - Charles River Laboratories International Inc. (CRL) revealed a profit for its third quarter that Increases, from last year

Charles River Laboratories International Inc. Announces Advance In Q3 Income 

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Dimensional US Small Cap ETF (Symbol: DFAS) where we have detected an approximate $395.2 million dollar inflow -- that's a 2.7% increase week over we

Noteworthy ETF Inflows: DFAS, IESC, SWKS, CRL

(RTTNews) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.

Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% 

The average one-year price target for Charles River Laboratories International (NYSE:CRL) (BMV:CRL) has been revised to $307.39 / share, up 11.46% from the prior estimate of $275.80 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and

Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc. News